Glaucoma is the leading cause of irreversible blindness worldwide. The primary cause of glaucoma is not known, but several risk factors have been identified, including elevated intraocular pressure and age. Loss of vision in glaucoma is caused by the death of retinal ganglion cells (RGCs), the neurons that convey visual information from the retina to the brain. Therapeutic strategies aimed at delaying or halting RGC loss, known as neuroprotection, would be valuable to save vision in glaucoma. In this review, we discuss the significant progress that has been made in the use of gene therapy to understand mechanisms underlying RGC degeneration and to promote the survival of these neurons in experimental models of optic nerve injury. Gene Therapy (2012) 19, 127-136; doi:10.1038/gt.2011; published online 6 October 2011
NEUROPROTECTION IN GLAUCOMA: RATIONALE AND CURRENT LIMITATIONS
Adult-onset glaucoma is an optic neuropathy that affects more than 50 million people around the world, with 47 million having bilateral (both eyes) blindness due to this disease. As more effective diagnostic tools become available, the number of cases is expected to rise, and a recent study predicts that there will be 70 million people with glaucoma in 2020. 1 Glaucoma is considered to be a group of diseases characterized by progressive optic nerve degeneration that results in visual field loss and irreversible blindness. The cause of glaucoma is unknown, but several risk factors have been identified, including high intraocular pressure, age and genetic predisposition. Open angle and angle-closure glaucoma, the most common forms of the disease, are often associated with high intraocular pressure. A crucial element in the pathophysiology of all forms of glaucoma is the death of retinal ganglion cells (RGCs; Figure 1 ) and, as these are central nervous system neurons, their loss is irreversible. At present, there is no cure for glaucoma, and the standard treatment is to lower intraocular pressure by medication or surgery. However, a significant proportion of patients continue to experience visual loss even when pharmacological treatments effectively reduce eye pressure. Therefore, novel therapeutic approaches are needed for its treatment and management.
Early-onset glaucoma, comprising primary congenital glaucoma and juvenile open-angle glaucoma, has a clear genetic basis. Between 10 and 30% of individuals with juvenile open-angle glaucoma have mutations in the gene encoding myocilin, 2,3 and, on average, B40% of people with primary congenital glaucoma have mutations in the gene encoding cytochrome P450 protein. 4 Both genes are expressed in the trabecular meshwork and ciliary body, and defects in these genes may cause ocular hypertension. The elucidation of the genetic basis underlying adult-onset glaucoma is difficult because the late onset of disease limits the number of individuals available for linkage analysis. However, at least 29 genetic loci for various forms of glaucoma and 12 causative genes have been identified by linkage studies. 5 Nevertheless, further work is required to clarify the relationship between gene defects and RGC pathophysiology in glaucoma before gene supplementation therapies can be developed. In addition, multiple genes, individual risk factors and environmental factors are likely to contribute to glaucoma onset. For these reasons, most gene therapy strategies for RGC neuroprotection, to date, are based on enhancing neuronal survival rather than correcting the primary genetic defect or injury source. As RGC death in human glaucoma typically occurs over several decades, strategies that do not address the initial insult, but might delay RGC death and support vision, are likely to be beneficial.
Effective neuroprotective strategies should take into account both the mechanisms of RGC death and the tools to halt or slow down this process. Gene therapy has gained considerable ground as a strategy to promote RGC neuroprotection after injury. With the advent of viral and nonviral agents suitable for in vivo gene delivery, a number of studies have now established proof of concept for gene therapy approaches to enhance the survival capacity of injured RGCs. This review focuses on the progress made to date on gene therapy strategies to promote RGC neuroprotection in experimental models of acute and chronic optic nerve damage. We also highlight the areas where there has been paucity in the use of gene therapy to manipulate pathways involved in RGC death, and discuss the challenges that lie ahead to move gene therapy toward clinical trials for RGC neuroprotection in glaucoma. The regulation of intraocular pressure through gene therapy targeted to the anterior structures of the eye has been reviewed recently elsewhere 6 and will not be addressed here.
TOOLS FOR GENE DELIVERY TO INJURED RGCS
Given the wide range of tools currently available for retinal gene transfer, we will focus here only on those that have had a significant impact on studies of RGC neuroprotection and discuss the advantages and disadvantages of each system.
Going viral: the use of virus vector-based approaches to target RGCs or surrounding cells Adeno-associated viral vectors. Among all currently available viral vector systems, the adeno-associated virus (AAV) vector has emerged as a favored tool for targeting adult RGCs. The ability of AAV vectors to transduce distinct retinal cell types depends on the virus serotype, the route of vector administration and the age of the host animal. Early studies in adult rat and mouse retinas identified AAV as an effective tool to transduce a large number of RGCs following intravitreal injection of the vector, 7-9 whereas subretinal AAV administration leads primarily to transduction of photoreceptors and retinal pigment epithelium (RPE). 10, 11 A variety of different AAV serotypes have been tested for retinal gene transfer, but the general consensus is that AAV-2 vectors provide the most efficient transduction of RGCs after intravitreal injection. 12 Although RGC-specific promoters have not yet been used to drive transgene expression following AAV transduction, constitutive viral promoters, such as the cytomegalovirus promoter, with a chicken b-actin enhancer have been shown to be effective. The combination of a chicken b-actin-containing promoter with the woodchuck hepatitis posttranscriptional regulatory element allowed transduction of B85% of rat RGCs within 2 weeks of intravitreal virus injection. 13 Tetracycline-regulatable promoter systems are also being investigated as a means to regulate AAVmediated transgene expression in RGCs. 14 Other advantages of the AAV vector system for in vivo gene delivery include that it is not pathogenic and has not been implicated in the etiology of any known human disease, it mediates long-term transgene expression that can last for several years in the retina 15 and it has low immunogenicity. In the absence of helper virus, wild-type AAV can integrate at a specific site on the 19q to establish latent infection. However, the lack of Rep proteins has been shown to compromise integration specificity, leading to random insertion of recombinant AAV. Although viral integration into the genome may contribute to the stability of AAV-mediated transgene expression, a careful evaluation of the risks associated with insertional mutagenesis is required before implementing AAV-based therapies. A disadvantage of AAV has been the size constraint for packaging genes larger than 4.7 kb. Although methods have been developed to increase the size of delivered transgenes by trans-splicing two independent vectors coadministered to the same tissue, 16 this remains a limitation of the AAV system. The laborious work needed to produce AAV vectors has often been regarded as a disadvantage. However, recent improvements in the protocols have facilitated the preparation of high-titer and pure AAV stocks following good manufacturing practice, which is a requirement for use in humans.
Adenoviral and lentiviral vectors. The most widely used adenoviral vectors for ocular gene transfer are based on the adenovirus (Ad)-5 backbone. These vectors were initially generated with deletions of the early region 1 (DE1) that contains genes required for virus replication, rendering vectors replication defective and more suitable for gene transfer into mammalian cells. A major disadvantage of these early Ad vectors is the strong cytotoxic and immune reaction elicited upon transduction of host cells. 17 Recent versions of Ad vectors have been produced in which the entire viral genome, except for the terminal repeat regions required for viral assembly, has been replaced by exogenous gene sequences. These so-called 'gutless' vectors, also referred to as helper-dependent Ad, exhibit considerably reduced immune response, but can only be produced in the presence of a helper virus that provides all the proteins required for viral replication. 18 These new vectors are less immunogenic and mediate longterm transgene expression following subretinal or intravitreal injection. [19] [20] [21] [22] For example, intravitreal administration of helper-dependent Ad promoted transgene expression for up to 1 year in transduced Müller glia. 22 A cardinal feature of Ad-5 vectors in the adult retina is that following intraocular injection, they efficiently transduce nonneuronal cell typesepithelial cells or glia-whereas their ability to infect neurons is poor. Intravitreal injection of Ad-5 results in preferential transduction of Müller cells, 23 an approach that has been useful to deliver genes encoding diffusible neurotrophic factors to promote RGC neuroprotection. 23, 24 Ad-5 vectors have also been shown to effectively transduce the RPE Figure 1 RGCs die in glaucoma. High intraocular pressure is a major risk factor for developing glaucoma. Ocular hypertension damage leads to the death of RGCs, the neurons that convey visual information from the retina to the brain. Loss of RGCs results in progressively worsening vision and blindness.
following subretinal injections, 25, 26 and transduced RPE cells have the potential to produce diffusible factors that enhance RGC survival. Further studies demonstrated that the arginyl-glycyl-aspartic acid domain, an integrin-binding motif, was responsible for the RPE tropism of Ad-5 vectors, and its deletion significantly increased transgene expression in the neural retina. 27 Under some experimental conditions, limited transduction of RGCs by Ad-5 has been observed. For example, introduction of Ad-5 to the superior colliculus or to the transected optic nerve stump results in retrograde transport of viral particles and subsequent gene expression in some RGCs. 28 Subretinal injection of lentiviral vectors results in transgene expression primarily by RPE cells, although other cells, including some photoreceptors, bipolar cells and Müller glia, may occasionally be transduced (see review by Balaggan et al. 29 ). Some studies have observed limited transduction of the inner retina when HIV-1 vectors are delivered intravitreally, 8 whereas others have reported some transduction of RGCs following intravitreal injection of HIV-2 vectors. 30 DNA-and RNA-based technologies to modify RGC gene expression Nonviral gene transfer strategies have the advantage of circumventing the safety concerns that stem from the potential immunogenic response and risk of chromosomal integration associated with viral vectors. The downside of nonviral approaches is that they yield low transduction rates, resulting in limited and often short-lived gene expression in vivo. These gene transfer strategies might be useful when transgene expression is required only during a critical time window to boost RGC survival. Sustained transgene expression using nonviral vectors might be attainable through multiple intraocular injections, topical (corneal) applications or intranasal delivery.
DNA plasmids or oligonucleotides are easy to prepare and can be readily injected into the eye, but they are not easily taken up by cells. Antisense oligonucleotides against pro-apoptotic molecules have been delivered to RGCs by intravitreal injection or by retrograde transport via injection in the superior colliculus, but these approaches resulted in only modest protection of axotomized RGCs due to limited transfection efficiency. 31, 32 Although liposomes have been shown to facilitate intravitreal or topical delivery of DNA to the inner retina, the usefulness of this approach in RGC neuroprotection remains largely unexplored. Among the physical methods to deliver DNA plasmids to RGCs, electroporation has received particular attention because it is safe, while providing effective gene transfer to these neurons in vivo. Electric field strength, pulse duration and stimulation pattern can be controlled to optimize transduction efficiency of RGCs. Transgene expression using electroporation can be detected as early as 2 or 3 days after gene delivery in vivo and can last up to 3 weeks. This approach has been used successfully to deliver neurotrophic factors and TXN thioredoxin genes to promote RGC survival in several models of optic nerve injury. [33] [34] [35] Small interference RNA (siRNA) has been successfully delivered to RGCs via injection into the superior colliculus; 36,37 however, the highly invasive nature of this approach limits its clinical application. Alternatively, siRNA can be injected intravitreally, leading to effective delivery to RGCs soon after administration (Figure 2 ). Although other retinal cells are likely to uptake siRNA delivered to the vitreous chamber, this strategy might be suitable for silencing genes that are specific or highly enriched in RGCs.
CRACKING THE CASE: GENE THERAPY STRATEGIES FOR RGC NEUROPROTECTION
There is little doubt that RGCs are the ultimate victims in glaucoma, but the primary culprits responsible for their demise are still at large. Glaucoma is an age-related, multifactorial disease and it is likely that several pathways converge to induce RGC loss. Although the signals that contribute to RGC degeneration in glaucoma are not well understood, a number of mechanisms have been proposed, including neurotrophic factor deprivation, activation of pro-apoptotic pathways, excitotoxic damage, oxidative stress, growth-inhibitory signals and reactive gliosis. The next sections discuss the use of gene delivery systems to increase our knowledge of the mechanisms that lead to RGC death after optic nerve damage and to manipulate molecular pathways to promote RGC survival in vivo.
A bad case of neuronal neglect: neurotrophic factor deprivation During development of the nervous system, young neurons require neurotrophic factors for their survival, differentiation and the establishment of synaptic connections. Neurotrophic factors are produced in limited amounts; therefore, only neurons that are exposed to optimal levels of these factors survive, whereas the rest die by apoptosis. There is substantial evidence that deprivation of neurotrophins, mainly brain-derived neurotrophic factor (BDNF) and nerve growth factor secreted by targets in the brain, leads to apoptotic death of RGCs during visual system development. 38 It has been proposed that blockade of axonal transport during eye pressure elevation in glaucoma leads to scarcity of target-derived neurotrophic factors and neuronal death. Indirect support for this hypothesis is provided by the observation that both anterograde and retrograde axonal transport in the optic nerve are impaired in animal models of glaucoma. 39, 40 Figure 2 RGC uptake siRNA injected into the vitreous chamber. Intravitreal injection of a Cy3-labeled siRNA results in robust Cy3 labeling of RGCs, visualized with Fluorogold (FG) (Fluorochrome, Denver, CO, USA). Scale bars¼40 mm. GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer; PS, photoreceptor segment.
Local sources of neurotrophic factors within the retina might also have a prominent role in adult RGC survival. Evidence for this idea stems from studies where RGC target tissue was ablated in adult animals, but neuronal loss was not detected until several months post lesion. [41] [42] [43] These findings suggest that retina-derived neurotrophic factors may temporarily support the survival of RGCs that have been disconnected from their targets. Collectively, these studies suggest that lack of neurotrophic factors, derived either from the target or the retina, may have a role in RGC death in glaucoma. Consequently, the supplementation of neurotrophic factors, either as exogenous proteins or by gene therapy, has been extensively explored as a neuroprotective strategy for injured RGCs. Because neurotrophic factors are secreted by the target cells, it is not a requirement for the transgenes to be expressed by RGCs. In fact, both autocrine or paracrine expression of neurotrophic factors by surrounding cells, which then influence the response of injured RGCs, have been an attractive gene therapy strategy 23, 24, 44, 45 (Figure 3) .
Among neurotrophic factors, the neurotrophin BDNF stands out for its potent protective effect on injured RGCs. Intraocular injection of exogenous BDNF protein or viral-mediated BDNF gene transfer using Ad (Ad.BDNF) or AAV (AAV.BDNF) promotes robust RGC survival after optic nerve transection. 23, [46] [47] [48] [49] [50] [51] The combination of BDNF gene therapy with additional therapies, including free radical scavengers and cell-permeable cyclic AMP (cAMP), further increases RGC neuroprotection. 24, 52 In experimental glaucoma induced by chronic eye pressure elevation, intraocular delivery of BDNF protein 53 or BDNF gene transfer using an AAV vector led to marked RGC neuroprotection. 54 For example, at 4 weeks of ocular hypertension, 32% of RGC axon loss was reported in eyes treated with AAV.BDNF compared with 52% in control eyes. 54 In spite of its robust prosurvival effect, BDNF does not stimulate RGC axon regeneration after optic nerve injury. Administration of BDNF protein or AAV.BDNF did not improve RGC axonal regrowth within the optic nerve or into peripheral nerve autologous grafts. 55, 56 Intriguingly, although the combination of BDNF and a preconditioning lens injury substantially enhanced RGC soma survival at 2 weeks post axotomy (71% survival compared with 44% in control eyes), this approach resulted in axonal dystrophy and regenerative failure. 57 Lens injury alone, on the other hand, promotes substantial axon regrowth in the order of 100-fold increase in the number of RGC axons that regenerate beyond the crush site, 58, 59 an effect that has been partly attributed to oncomodulin, a novel macrophage-derived factor that promotes cAMP-dependent axonal regeneration. 60 Long-term studies have demonstrated that the pro-survival effect of BDNF on RGCs is temporary: it delays, but does not prevent, the onset of RGC death. 23, 49 Administration of BDNF protein by repeated intravitreal injections or osmotic mini pumps failed to extend the time course of RGC neuroprotection. 49, 61 Adenoviral vector-mediated gene delivery of BDNF to Müller cells provided a sustained source of neurotrophin, leading to a 4.5-fold increase in the number of surviving RGCs at 16 days after axotomy, but this neuroprotective effect was transient and declined at 28 days post injury. 23 BDNF exerts its biological effect upon binding to its cognate receptor TrkB, therefore the transient survival effect of BDNF was attributed to a reduction in RGC cell surface receptor levels. 62 Consistent with this, AAV-mediated gene transfer of TrkB to RGCs markedly increased the duration and level of BDNF-induced neuroprotection of these neurons. 7 Specifically, AAV.TrkB gene therapy, combined with exogenous BDNF administration, increased the survival of RGCs by 76% at 2 weeks after optic nerve lesion, a time when o10% of these remain in nontreated retinas, hence substantially extending RGC survival well beyond the shorter effect of BDNF protein alone.
Another prominent neurotrophic factor that effectively promotes RGC neuroprotection in addition to axon regrowth is the ciliary neurotrophic factor (CNTF). Exogenous or endogenous CNTF protein has been shown to stimulate RGC survival after optic nerve axotomy or crush 63, 64 in experimental glaucoma 65, 66 and acute autoimmune optic neuritis. 67 Four weeks after laser-induced ocular hypertension, there was a 15% increase in the number of RGC axons in eyes treated with AAV.CNTF compared with eyes treated with a control vector. 66 Adenoviral-mediated CNTF gene transfer was reported to increase retinal CNTF and CNTF receptor-a levels, which correlated with a 7% increase in the survival of axotomized RGCs. 45 Lentiviral-mediated CNTF gene transfer was also reported to enhance survival of axotomized RGCs. 68 More recently, AAV-mediated expression of a secretable form of CNTF was shown to stimulate RGC survival as well as axon regeneration after optic nerve crush or peripheral nerve graft transplantation, an effect that was substantially enhanced in the presence of a cell-permeable cAMP analog. 48, 63 Three weeks after graft transplantation, there was a sixfold increase in the number of surviving RGCs that regenerated an axon when CNTF gene transfer was combined with increased cAMP levels compared with control optic nerves. 63 Other key neurotrophic factors that have been explored using gene therapy approaches regarding their ability to regulate RGC survival and regeneration are fibroblast growth factor-2 (FGF-2) and glial cell line-derived neurotrophic factor (GDNF). FGF-2 is upregulated after injury in cells of the inner nuclear layer and ganglion cell layer of the adult retina, as well as in the optic nerve and in the optic tract. 69 AAV-mediated FGF-2 gene transfer resulted in a 10-fold increase in the number of injured RGC axons that regenerated past the lesion site at 2 weeks after optic nerve micro-crush lesion. 70 The regenerative response to FGF-2 upregulation was supported by the finding that FGF receptor-1 and heparan sulfate, known to be essential for FGF-2 signaling, are expressed by adult rat RGCs. In contrast to BDNF, FGF-2 transgene expression stimulated RGC axon regrowth, but led to only modest survival of injured RGCs. 70, 71 Intraocular injection of GDNF protects axotomized RGCs, 72 albeit with less efficacy than BDNF. Combined treatment of BDNF and GDNF resulted in 65% and 110% increase in the survival of axotomized RGCs compared with BDNF or GDNF alone, respectively. 73 GDNF gene transfer using an adenoviral vector or electroporation conferred protection of RGCs after optic nerve transaction. 44, 74 Collectively, these studies highlight the potential of gene therapy to upregulate retinal neurotrophic factors that stimulate survival and/or regeneration of injured RGCs.
Inhibition of apoptotic pathways and manipulation of mitochondrial function
Apoptosis or programmed cell death is a common mechanism of neuronal loss in the injured or degenerating visual system. The hallmark structural features of apoptosis are cellular round up, retraction of pseudopodia, reduction of cellular volume, nuclear fragmentation, modification of cytoplasmic organelles, plasma membrane blebbing and engulfment by resident phagocytes. RGCs have been shown to die by apoptosis in optic nerve acute lesion models (axotomy and crush), 75 experimental glaucoma 76 and human glaucoma. 77 Apoptotic RGC death was recently confirmed by in vivo real-time visualization in ocular hypertensive rat eyes. 78 The apoptotic process can be triggered by various stimuli and involves extrinsic and intrinsic pathways (Figure 4) . Extrinsic signals include an array of death-receptor ligands: Fas-L, tumor necrosis factor-a (TNF-a) and TNF-related apoptosis-inducing ligands, which bind to their respective receptors (Fas, TNF receptor and TNF-related apoptosis-inducing Figure 4 Extrinsic and intrinsic apoptotic pathways regulating RGC death. The apoptotic death of RGCs can be triggered by various stimuli and involves extrinsic and intrinsic pathways. Extrinsic signals include the death-receptor ligands Fas-L, TNF-a and TNF-related apoptosis-inducing ligand, and their respective receptors, which induce RGC death. Lack of neurotrophic factors may result in deficits of pro-survival pathways, including extracellular signalregulated kinase 1/2 and phosphatidylinositol-3 kinase. The intrinsic pathway converges on the Bcl-2 family members: pro-apoptotic (Bax, Bad and Bid) or antiapoptotic (Bcl-2 and Bcl-XL), which regulate the mitochondrial outer membrane permeabilization. These proteins control the release of cytochrome c into the cytosol, which can activate the caspases, executioners of apoptosis. The target molecules that have been used in gene therapy studies of RGC neuroprotection are shaded.
ligand receptor) to induce cell death. Evidence of TNF-a and Fas ligand upregulation in glaucoma has been observed. 79 Death receptor activation results in the recruitment of intracellular adaptor Fasassociated death domain, which then recruits caspase-8 leading to caspase-3 activation and subsequent cell death. Although these molecular pathways represent important targets for RGC neuroprotection, they have been largely unexplored using gene therapy tools.
In contrast, the intrinsic apoptotic pathway has been the target of many studies using gene therapy, with the common goal of rescuing RGCs from apoptotic death. There is substantial evidence that neurotrophic factors suppress the intrinsic apoptotic cascade by activating intracellular survival signals. Upon binding to their cognate tyrosine kinase receptors, most neurotrophic factors stimulate two primary pro-survival signaling pathways: the extracellular signalregulated kinase 1/2 and the phosphatidylinositol-3 kinase pathways. 80 Some factors, such as CNTF, can also activate the Janus kinase/signal transducer and activator of transcription 3. 81 AAV-mediated gene transfer of constitutively active mitogen activated protein kinases/extracellular signal-regulated kinase kinase 1, the obligate upstream activator of extracellular signal-regulated kinase 1/2, resulted in robust survival of RGCs at 2 weeks after axotomy (27% increase over controls) and at 5 weeks of ocular hypertension (38% increase over controls) in rats. 82, 83 Consistent with the lack of RGC axon regeneration observed with BDNF, gene transfer of constitutively active mitogen activated protein kinases/ extracellular signal-regulated kinase kinase 1 did not promote axon regrowth in the damaged optic nerve. 82 Gene transfer of signaling molecules downstream of CNTF, such as Janus kinase/signal transducer and activator of transcription 3, has not yet been reported, but would help clarify the role of these intermediaries in RGC survival and regeneration. In contrast to protein tyrosine kinases that promote neuronal survival, there are several pro-apoptotic protein kinases that contribute to RGC death, such as the c-Jun N-terminal kinase. 84 c-Jun, activated by c-Jun N-terminal kinase phosphorylation, mediates transcription of pro-apoptotic genes and has been shown to be upregulated in rat and monkey models of glaucoma. 85, 86 siRNA-mediated gene expression knockdown of c-Jun in RGCs resulted in a threefold increase in RGC survival at 2 weeks after optic nerve lesion. 37 These studies support the notion that gene therapy strategies that modulate the activity of signaling intermediaries may be beneficial for RGC neuroprotection in glaucoma.
The battleground of apoptosis is the mitochondria, the organelle where cell fate is decided. The Bcl-2 family members were the first molecular targets linked to mitochondrial function to be studied in the context of RGC death. 87 Transgenic overexpression of the antiapoptotic Bcl-2 protein resulted in sustained RGC survival after axotomy. 88 Furthermore, AAV-mediated gene transfer of Bcl-XL or BAG1, a Bcl-2-associated protein, promoted RGC survival in optic nerve cut or crush models. 89, 90 At 8 weeks after axotomy, 46% of Bcl-XL overexpressing RGCs survived compared with only 6% in control groups. 89 Deletion of the pro-apoptotic Bax gene was shown to be neuroprotective for RGC soma, but failed to prevent axon degeneration in DBA/2J mice, a mouse strain that spontaneously develops chronic age-related glaucoma. 91 Intriguingly, BAX knockdown through injection of siRNA into the optic nerve did not result in significant protection of axotomized RGCs. 92 In the final steps of the intrinsic apoptotic pathway, BAX molecules translocate to the mitochondrial outer membrane and form pore structures that facilitate cytochrome c release into the cytoplasm. Cytochrome c binds to Apaf-1 to form the apoptosome, a complex that recruits and activates pro-caspase-9, which in turn activates downstream effector caspases. Apaf-1 gene knockdown in RGCs using siRNA has been shown to promote neuronal survival. 37 In contrast, the suppression of apoptosis using caspase inhibitors has been investigated with modest success. 93 An exception to this are studies using siRNA to knockdown caspase-2 expression in RGCs. A recent study demonstrated that caspase-2 is expressed and activated primarily in RGCs following optic nerve injury. 94 Moreover, inhibition of caspase-2 expression using a chemically modified siRNA delivered intravitreally led to robust RGC survival after optic nerve crush or cut. 94 This strategy is currently in phase 1 clinical trials for non-arteritic anterior ischemic optic neuropathy (http://clinicaltrials.gov/ct2/show/NCT01064505?term¼ Quark&rank¼3). Another effective approach has been to target baculoviral IAP repeat-containing 4 (BIRC4), also known as X-linked inhibitor of apoptosis protein, a member of the inhibitors of apoptosis family and a direct inhibitor of several effectors including caspase-3, -7 and -9. 95 AAV-mediated gene transfer of BIRC4/X-linked inhibitor of apoptosis protein successfully promoted RGC protection in chronic and acute ocular hypertension models. 96, 97 For example, at 12 weeks of ocular hypertension there was a 2.4-fold increase in the number of surviving RGC axons in AAV.BIRC4-treated eyes compared with control eyes. 96 Of interest, combined administration of adenoviral vectors encoding X-linked inhibitor of apoptosis protein or GDNF had a synergistic effect on the survival of axotomized RGCs, which was greater than upregulation of each individual pathway. 44 Therefore, the use of gene therapy strategies that target multiple antiapoptotic pathways appears to be a promising avenue to increase RGC survival after optic nerve damage.
An alternative neuroprotective strategy that is being developed for the treatment of optic neuropathies, and might be relevant to glaucoma, is the regulation of genes encoding integral mitochondrial proteins. The gene encoding OPA-1, a protein embedded in the inner mitochondrial membrane, is mutated in the majority of patients with autosomal-dominant optic atrophy, a condition characterized by RGC degeneration and childhood blindness. OPA-1 is a GTPase dynaminlike protein that mediates mitochondrial fusion, thus loss of OPA-1 function leads to mitochondrial fragmentation, cytochrome c release, mitochondrial DNA damage and increased reactive oxygen species. 98 Gene therapy for mitochondrial disorders is challenging because the mitochondrial inner membrane is a substantial barrier for gene delivery. A promising technology involves allotopic expression where the therapeutic gene is introduced into the nuclear genome, and the gene product is then imported into mitochondria using a targeting sequence. Overexpression of OPA-1 by AAV-mediated gene transfer increased RGC survival, while decreasing the number of reactive astroglia and microglia in DBA/2J mice. 99 Leber's hereditary optic neuropathy, a rare condition characterized by RGC death, is also caused by mutations in mitochondrial DNA. Most cases are due to point mutations in genes encoding several subunits of the nicotinamide adenine dinucleotide-ubiquinone oxidoreductase, which is essential for complex I activity in the electron transport chain. RGCs with mutated mitochondrial DNA undergo apoptosis through calcium-dependent and caspase-independent pathways, a process also associated with the release of toxic mitochondrial factors to the cytosol (for example, cytochrome c, apoptosis-inducing factor and endonuclease G). Allotopic delivery by electroporation of the wild-type human ND4 subunit gene, which carries prevalent mutations in Leber's hereditary optic neuropathy patients, promoted RGC neuroprotection in a rat model of Leber's hereditary optic neuropathy. 100 Specifically, B38% decrease in RGC counts was observed in animals that expressed the mutant ND4 compared with wildtype ND4 at 48 days after electroporation. 100 More recently, AAV-mediated allotopic delivery of ND4 was shown to be safe in a phase I clinical trial. 101 Toxic enablers: channels and receptors involved in RGC damage Excitotoxicity, ionic imbalance and oxidative stress have been proposed to contribute to RGC loss in glaucoma. These pathways of RGC injury, activated by numerous receptors and channels, can activate downstream mediators of cell death through multiple points of convergence. The central dogma of excitotoxicity is that excess glutamate binds to cell surface glutamate receptors on neurons, primarily N-methyl-D-aspartate receptors, triggering massive Ca 2+ influx and apoptosis. However, N-methyl-D-aspartate receptor antagonists have consistently failed in clinical trials, including a recent trial testing the efficacy of memantine in glaucoma, 102 which suggests that other mechanisms contribute to excitotoxic damage in vivo. Alternative models include a role for neighboring cells, primarily glia, in excitotoxic RGC demise. For example, a recent study demonstrated that Müller cells are extremely sensitive to an acute excitotoxic insult and respond by upregulating TNF-a, which then mediates RGC loss. 103 In the case of chronic, neurodegenerative diseases where an excitotoxic component is thought to be involved, such as in glaucoma, blockade of glutamate receptors may not ameliorate disease progression unless other damaging molecules (for example, glia-derived TNF-a) are also inhibited. The molecular pathways involved in RGC excitotoxicity have been targeted using drugs and pharmacological agents, but, so far, gene therapy has not been explored. Given the complexity of glaucoma, it is likely that more than one signaling pathway will need to be targeted to achieve neuroprotection. Gene therapy might provide the versatility required to selectively target different molecular pathways, possibly in different cell types, to optimize RGC viability.
Other pathways converging onto the apoptotic machinery are mediated by ionic imbalance, leading to cell shrinkage and death. Indeed, cell shrinkage precedes mitochondrial dysfunction and apoptosome formation, and has been shown to occur in RGCs subjected to high pressure. 104 Importantly, cell shrinkage and apoptosis are accompanied by increased K + currents and depletion of intracellular K + ; therefore, K + channels are being investigated in the context of RGC death. A recent study demonstrated that siRNA-mediated knockdown of K + channels of the Shaker (Kv1) family effectively supports the survival of axotomized RGCs. 36 This approach is substantially more specific than common, nonselective channel blockers.
Oxidative stress, caused by the imbalance between the production of reactive oxygen species and their breakdown by antioxidants, has been recognized as another central contributor to RGC injury and death. Reactive oxygen species superoxide increases in RGCs following optic nerve axotomy, and RGC death is delayed in vivo when intracellular superoxide levels are decreased. 105 Administration of pegylated superoxide dismutase-1, which catalyzes the dismutation of superoxide into oxygen and hydrogen peroxide, functions as an antioxidant and attenuates RGC death. 105 Therefore, blockade of superoxide generation might be beneficial for injured RGCs in glaucoma. Another strategy involves heme oxygenase, which alleviates tissue injury not only by acting as an antioxidant but also by modulating the inflammatory response and activating innate antiapoptotic pathways. Consistent with this, Ad-mediated heme oxygenase gene transfer protected RGCs against ischemia/reperfusion injury 106 and pressure-induced ischemia. 107 Thus, the modulation of antioxidants via gene therapy might be a promising approach to protect RGCs from glaucomatous damage.
Overcoming axon growth inhibition Neuroprotection in glaucoma aims at preserving the structure and function of remaining RGCs. It is likely, however, that a number of RGCs in glaucoma undergo axonal damage and/or retraction of synaptic terminals that interrupt neurotransmission. For those neurons, in addition to neuroprotection, regenerative strategies that promote axonal regrowth and enhance synaptic connectivity might be required. Similar to other central nervous system neurons in adult mammals, RGCs have a limited capacity to regenerate an axon within the optic nerve. If these neurons are provided with a permissive environment, such as a peripheral nerve graft, they have the ability to regrow axons for long distances and form new synaptic connections. 108 The limited ability of RGCs to regenerate an axon is partly due to the presence of myelin-associated growth inhibitory molecules. Three inhibitors have been identified in myelin: Nogo-A, myelinassociated glycoprotein and oligodendrocyte-myelin glycoprotein. 109 The Nogo receptor (NgR) serves as a high-affinity receptor for Nogo-A, myelin-associated glycoprotein and oligodendrocyte-myelin glycoprotein, and has two partners responsible for signal transduction: p75 NTR and the NgR-interacting protein (LINGO-1). 109 Adult RGCs do not express p75 NTR , 110 and a newly identified co-receptor, named TROY, has been shown to interact with NgR and LINGO-1 to promote growth inhibition in these neurons. 111 The strategy to block NgR has received attention because it offers a single target to neutralize signaling via Nogo, myelin-associated glycoprotein or oligodendrocyte-myelin glycoprotein. Expression of a dominant-negative form of NgR in RGCs using recombinant AAV led to appreciable axonal regeneration, but only when combined with a preconditioning lens injury that elicited ocular inflammation and axon regrowth. 112 Therefore, overcoming myelin-derived inhibitory signals is not sufficient to promote RGC axon regeneration unless this strategy is combined with treatments that stimulate axonal growth.
Damage to the optic nerve triggers a series of events that lead to the formation of a glial scar. Although the glial scar is part of a self-repair process that protects the fragile neural tissue and helps repair the blood-brain barrier, it is also a major physical and chemical obstacle that prevents axonal regeneration. The glial scar in central nervous system tissue contains a large number of reactive astrocytes that secrete potent inhibitors of axon growth such as chondroitin sulfate proteoglycans. In glaucoma, astrocytes in the optic nerve head undergo cell hypertrophy, leading to major alterations in the biochemical composition of the extracellular matrix and biomechanical properties of the tissue surrounding RGC axons, 113 which might contribute to regenerative failure. Gene therapy represents a potential tool to modulate gene expression in astrocytes to selectively regulate expression of inhibitory factors and enhance RGC axon regeneration, while preserving the astrocytic functions that facilitate the nerve repair processes.
The signaling molecules that contribute to RGC axon regeneration are being elucidated and are promising avenues to tackle the complex problem of optic nerve repair through gene therapy strategies. Several growth inhibitory signals converge on the Rho GTPase pathway to halt axonal growth. Blockade of RhoA activity using cell-permeable C3 ribosyltransferase, directly applied to the transected optic nerve or delivered to RGCs by an AAV vector, resulted in twofold increase in axonal regrowth at 2 weeks after crush injury. 114, 115 Gene knockdown of the mammalian sterile 20-like kinase-3b by short hairpin RNA delivered to RGCs using AAV prevented axon growth, demonstrating a role for this kinase in optic nerve regeneration. 116 AAV-mediated deletion of phosphatase and tensin homolog, a negative regulator of the mammalian target of rapamycin, promoted robust RGC axon regeneration, 117 and this effect was markedly enhanced by cAMP and the pro-inflammatory agent zymosan. 118 
SUMMARY AND FUTURE PERSPECTIVES
The medical need for neuroprotective therapies for glaucoma is undeniable. In the last 10 years, there has been tremendous progress in the use of gene therapy strategies not only to understand the molecular basis of RGC death, but also to stimulate the survival and regeneration of these neurons in a variety of preclinical models of optic nerve injury. Among available recombinant viral vectors, AAV-2 has received particular attention because of its ability to mediate infection of a large number of adult RGCs in vivo with relatively high specificity. Novel nonviral approaches to modulate RGC gene expression, including electroporation and siRNA delivery, are also being investigated with promising results. Several key molecular pathways that dictate the fate of RGCs after optic nerve injury have been explored. The modulation of neurotrophic factor expression and stimulation of pro-survival signaling pathways have been extensively studied, and several candidate molecules have emerged as promising therapeutic targets. Strategies to block the intrinsic apoptotic pathway, toxic mediators and axon growth inhibitors have also been explored with success, and allotopic gene transfer to treat mitochondrial dysfunction is a promising avenue for several optic neuropathies including glaucoma.
Gene therapy has moved rapidly from promising data obtained in the laboratory to ongoing clinical trials for blinding diseases such as Leber's congenital amaurosis. In the case of neuroprotective gene therapy for adult-onset glaucoma, substantial hurdles still need to be overcome to translate successful preclinical findings to clinical applications. For example, what molecular pathway should be targeted for RGC neuroprotection? Unlike many inherited retinal degenerations in which supplementation of a healthy copy of the affected gene is a sensible approach, the heterogeneity of factors contributing to RGC death in glaucoma makes it difficult to settle on any one pathway. There might be patients who experience compromised retrograde axonal transport along the optic nerve and target-derived neurotrophin deprivation, whereas others might suffer from increased oxidative stress and reduced antioxidant defense mechanisms. Moreover, some individuals may suffer from alterations in multiple pathways that converge to trigger or exacerbate RGC death. The availability of novel biomarkers for glaucoma may serve to identify molecular deficits in individual patients and, eventually, to personalize gene therapy interventions. Unlike pharmacological treatments, gene therapy will allow the simultaneous manipulation of multiple pathways with relatively high specificity.
Another important issue relates to the effect of long-term modification of gene expression, such as that provided by AAV, in glaucoma. For example, neurotrophic factor supplementation by gene therapy is a promising strategy to promote RGC survival in several models of optic nerve damage, but the long-term effect and safety of increased diffusible neurotrophin levels in the retina are currently unknown. Sustained AAV-mediated expression of CNTF or BDNF leads to changes in the dendritic structure of transduced RGCs. 56 It will be important to establish whether these morphological changes have a tangible effect on RGC electrophysiological function. The use of viral vectors containing genes driven by regulatable promoters, or the use of DNA or siRNA technologies that afford transient gene expression may resolve some of these issues. In conclusion, a number of studies have demonstrated proof of principle for the use of gene therapy for neuroprotection of injured RGCs, and several promising molecular pathways have been elegantly delineated. The challenge now is to assess how this wealth of knowledge can be translated into potential gene therapies for neuroprotection in glaucoma.
